AI Precision Medicine Momentum: Social media chatter highlights Tempus AI's expansive multimodal dataset powering diagnostics and treatments in oncology and cardiology. Investors applaud high-margin data services growth nearing 30% organically, alongside strategic acquisitions like Ambry Genetics adding revenue streams. The platform's flywheel effect draws praise for scalable pharma partnerships.
Valuation Views Amid Dip: Discussions note the stock trading at around 7.6 times annualized revenues, below recent averages, prompting some to accumulate shares. Robust cash reserves offer multi-year runway despite operating burn, countering short arguments on losses. Bears cite competition, but bulls emphasize improving margins and EBITDA positivity.
Earnings Anticipation Builds: Traders eye upcoming March earnings for confirmation of growth trajectory and AI monetization. Technical patterns suggest bounces from support levels near $60. Sentiment tilts bullish on healthcare AI disruption potential.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI Insider Trading Activity
Tempus AI insiders have traded $TEM stock on the open market 115 times in the past 6 months. Of those trades, 0 have been purchases and 115 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 62 sales selling 1,696,787 shares for an estimated $127,452,760.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 20 sales selling 57,559 shares for an estimated $4,330,040.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 7 sales selling 34,751 shares for an estimated $2,499,084.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 9 sales selling 29,864 shares for an estimated $2,144,365.
- THEODORE LEONSIS sold 20,000 shares for an estimated $1,516,600
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 5 sales selling 8,499 shares for an estimated $592,859.
- WAYNE A.I. FREDERICK sold 3,675 shares for an estimated $283,820
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 4 sales selling 3,738 shares for an estimated $262,337.
- JENNIFER A DOUDNA has made 0 purchases and 2 sales selling 2,602 shares for an estimated $188,684.
- DAVID R EPSTEIN has made 0 purchases and 4 sales selling 1,240 shares for an estimated $92,579.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI Revenue
Tempus AI had revenues of $334.2M in Q3 2025. This is an increase of 84.72% from the same period in the prior year.
You can track TEM financials on Quiver Quantitative's TEM stock page.
Tempus AI Hedge Fund Activity
We have seen 267 institutional investors add shares of Tempus AI stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GC WEALTH MANAGEMENT RIA, LLC added 6,761,507 shares (+inf%) to their portfolio in Q4 2025, for an estimated $399,266,988
- D. E. SHAW & CO., INC. added 1,605,757 shares (+380.8%) to their portfolio in Q3 2025, for an estimated $129,600,647
- BANK OF AMERICA CORP /DE/ added 1,277,244 shares (+112.9%) to their portfolio in Q3 2025, for an estimated $103,086,363
- BNP PARIBAS FINANCIAL MARKETS removed 1,101,434 shares (-86.4%) from their portfolio in Q4 2025, for an estimated $65,039,677
- VOLORIDGE INVESTMENT MANAGEMENT, LLC added 1,039,176 shares (+183.0%) to their portfolio in Q3 2025, for an estimated $83,871,894
- BAILLIE GIFFORD & CO removed 950,999 shares (-9.8%) from their portfolio in Q4 2025, for an estimated $56,156,490
- VANGUARD GROUP INC added 817,014 shares (+8.7%) to their portfolio in Q4 2025, for an estimated $48,244,676
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Tempus AI Government Contracts
We have seen $18,051,934 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 12/22/2025
- BTIG issued a "Buy" rating on 11/25/2025
- Morgan Stanley issued a "Overweight" rating on 11/11/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/07/2025
- Guggenheim issued a "Buy" rating on 09/26/2025
To track analyst ratings and price targets for Tempus AI, check out Quiver Quantitative's $TEM forecast page.
Tempus AI Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 8 analysts offer price targets for $TEM in the last 6 months, with a median target of $87.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $80.0 on 12/22/2025
- Casey Woodring from JP Morgan set a target price of $80.0 on 12/15/2025
- Tejas Savant from Morgan Stanley set a target price of $85.0 on 12/02/2025
- Mark Massaro from BTIG set a target price of $105.0 on 11/25/2025
- David Westenberg from Piper Sandler set a target price of $80.0 on 11/11/2025
- Yi Chen from HC Wainwright & Co. set a target price of $89.0 on 11/07/2025
- Ryan MacDonald from Needham set a target price of $100.0 on 11/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
